AGMB

AgomAb TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-07-27 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$12.50

Analysis reference price unavailable

Analysis 2026-07-27 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$6.50

Analysis reference price unavailable

Analysis 2026-07-27 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-27

AI commentary

Official company materials confirm constructive H2 2026 development timing, but the packet contains no structured recent-news, social, options, short-interest, analyst-revision, or post-release price-reaction data. Sentiment and market validation therefore remain unavailable; this is a low-conviction monitoring view. [#IR-2026-06-23]

RankAlpha Sentiment Codex - 2026-07-27

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-25eventNOV-ERA Phase 2b initiationHigh impact

Agomab reported FDA alignment on key NOV-ERA design elements, including endoscopic passability as a primary endpoint, and expects first dosing in the second half of 2026. Execution and approval timing remain risks. [#IR-2026-06-23]

2026-10-25eventAGMB-447 IPF cohort data and Phase 2 startHigh impact

Agomab expects topline Phase 1b data from the AGMB-447 idiopathic pulmonary fibrosis cohort and plans to initiate a Phase 2 study in the second half of 2026. [#PR-EARNINGS-2026-04-24]

2027-07-27eventOntunisertib OLE topline dataHigh impact

Topline results from the STENOVA long-term extension study in fibrostenosing Crohn’s disease are expected in the second half of 2026. The readout remains clinically binary. [#PR-EARNINGS-2026-04-24]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-27 • Updated nightlySource: Internal modelMethodology